21.12.05 DGAP-Ad hoc: MOLOGEN AG <DE0006637200>: Ad hoc announcement §15 WpHG / Sonstiges - 500 Beiträge pro Seite

[ad_hoc [wO]]

Ad hoc announcement §15 WpHG

Sonstiges

MOLOGEN AG: Preparation period for dSLIM clinical studies can be shortened

Ad hoc announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
------------------------------------------------------------------------------

MOLOGEN AG (ISIN DE0006637200) has received a confirmation from the
responsible regulatory authority, that the production of DNA based
immunomodulator dSLIM does not require a manufacturing authorization according
to the German pharmaceutical law(Arzneimittelgesetz). Moreover dSLIM does not
fall under German gene technology law (Gentechnikgesetz).

Therewith MOLOGEN can produce dSLIM under "Good Manufacturing Practice", GMP
guidelines and under its own Quality Assurance.

With this notification the preparation period for dSLIM clinical studies is
considerably shortened in formal and temporal terms.

About MOLOGEN
MOLOGEN uses its proprietary DNA technologies to create and develop treatments
for high-unmet-need illnesses. The main focuses are the unique and patented
MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing
DNA-based vaccines and therapeutics to prevent or cure a wide range of
diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology
companies to be floated on the stock exchange. The MOLOGEN shares are traded
on the Geregelter Markt in Frankfurt

MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland

ISIN: DE0006637200
WKN: 663720
Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in
Berlin-Bremen, Hamburg und Stuttgart

End of ad hoc announcement (c)DGAP 21.12.2005

Autor: import DGAP.DE (© DGAP),15:19 21.12.2005

[[KERN]Codex]